Drug Profile
Research programme: droxidopa controlled-release - Lundbeck
Alternative Names: CR droxidopa; Northera™ controlled release; Threo-DOPS controlled releaseLatest Information Update: 01 Jul 2014
Price :
$50
*
At a glance
- Originator Chelsea Therapeutics
- Developer Lundbeck A/S
- Class Amino acids; Catecholamines; Small molecules
- Mechanism of Action Adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hypotension
Most Recent Events
- 01 Jul 2014 Discontinued - Preclinical for Hypotension in USA (PO, controlled-release)
- 24 Jun 2014 Chelsea Therapeutics has been acquired by Lundbeck A/S
- 16 Dec 2011 Preclinical trials in Hypotension in USA (PO)